Cancer-related Molecular Pathways
Cancer-related Molecular Pathways is a research topic within Oncology. Science Explorer counts 48k research works in it since 1950. 22.9% of them reached the world's top 10% most cited for their field and year.
This cluster of papers focuses on the p53 signaling network, exploring its role in cell cycle regulation, tumor suppression, cancer therapy, apoptosis, and the impact of mutations. The papers cover various aspects of p53-MDM2 interaction, cyclin-dependent kinases, and the intricate mechanisms of p53 regulation in the context of cancer research.
- p53
- cell cycle
- MDM2
- tumor suppression
- cancer therapy
- apoptosis
- CDKs
- mutation
- regulation
- oncogene
- Research works
- 48k fractional, since 1950
- In the world top 10%
- 11k per year above
- Top-10% rate
- 22.9% share of its works in the world top 10%
- Growth, 2013–17 → 2018–22
- -14% the tick is no change
This ranks research output and citation impact. It says nothing about the quality of diagnosis, treatment or care.
Which countries lead Cancer-related Molecular Pathways research?
By volume, China and the United States publish the most (1.2k and 1.2k works in 2022–2025).
By volume, 2022–2025
- 1 China 1.2k works
- 2 United States 1.2k works
- 3 India 291 works
- 4 Japan 199 works
- 5 Germany 150 works
- 6 United Kingdom 143 works
- 7 Italy 143 works
- 8 South Korea 133 works
- 9 Canada 96 works
- 10 Spain 84 works
How concentrated that is
The same countries as shares of everything the list above accounts for. A node where two countries do two thirds of the work and one spread evenly across twelve read alike as a ranking and not at all alike here.
Shares of the rows listed above, not of the whole node.
Which institutions lead Cancer-related Molecular Pathways research?
By volume in 2022–2025, The University of Texas MD Anderson Cancer Center publishes the most Cancer-related Molecular Pathways research, followed by University of North Carolina at Chapel Hill and Chinese Academy of Medical Sciences & Peking Union Medical College.
By volume, 2022–2025
- 1 The University of Texas MD Anderson Cancer CenterUnited States 50 works
- 2 University of North Carolina at Chapel HillUnited States 25 works
- 3 Chinese Academy of Medical Sciences & Peking Union Medical CollegeChina 18 works
- 4 Dana-Farber Cancer InstituteUnited States 17 works
- 5 Memorial Sloan Kettering Cancer CenterUnited States 16 works
- 6 Sun Yat-sen UniversityChina 16 works
- 7 Harvard UniversityUnited States 15 works
- 8 Sichuan UniversityChina 15 works
- 9 Zhejiang UniversityChina 15 works
- 10 University of PennsylvaniaUnited States 14 works
Who are the leading researchers in Cancer-related Molecular Pathways?
The most-cited researchers publishing on Cancer-related Molecular Pathways include Douglas Hanahan, Robert A. Weinberg and Guido Kroemer.
- 1 Douglas Hanahan United States 10k citations
- 2 Robert A. Weinberg United States 8.3k citations
- 3 Guido Kroemer France 4.2k citations
- 4 Gordon B. Mills United States 3.7k citations
Ranked by citations received across their whole record, among researchers with at least three works on this topic.
Where is Cancer-related Molecular Pathways research done?
The largest centres of Cancer-related Molecular Pathways research in 2022–2025 are Beijing (China), Shanghai (China), Houston (United States) and Guangzhou (China). Among places with at least 20 works in it, it is an unusually large share of all research in Houston and Bethesda.
Largest cities, 2022–2025
Where it is the local speciality
- HoustonUS · 77.0 works6.8×
- BethesdaUS · 31.1 works5.5×
Location quotient: how much more of its research is in Cancer-related Molecular Pathways than the world average.
Where is the best place to study Cancer-related Molecular Pathways?
Among universities, judged by research, China Pharmaceutical University, Karolinska Institutet and Harvard University score highest, combining excellence, specialisation, size, growth and international reach. Research strength is one signal when choosing where to study; it does not measure teaching.
One dot per university in the table below. The upper left is the interesting corner: small places doing unusually strong work.
| # | University | Score | Top 10% | Specialisation | Works | Growth |
|---|---|---|---|---|---|---|
| 1 | China Pharmaceutical UniversityChina | 64.0 | 25.6% | 14.6× | 14 | +70.6% |
| 2 | Karolinska InstitutetSweden | 46.0 | 25.8% | 5.4× | 11 | -30.2% |
| 3 | Harvard UniversityUnited States | 45.3 | 33.2% | 2.6× | 15 | -27.0% |
| 4 | Zhejiang UniversityChina | 44.7 | 33.3% | 1.6× | 15 | +19.8% |
| 5 | Cornell UniversityUnited States | 44.0 | 39.0% | 2.0× | 9 | -4.5% |
| 6 | Sichuan UniversityChina | 40.6 | 30.8% | 1.9× | 15 | +9.8% |
| 7 | China Medical UniversityChina | 40.4 | 22.8% | 8.0× | 12 | -38.0% |
| 8 | Sun Yat-sen UniversityChina | 40.2 | 28.7% | 2.2× | 16 | +2.2% |
| 9 | Nanjing Medical UniversityChina | 38.2 | 26.1% | 5.0× | 11 | -14.0% |
| 10 | Chinese Academy of Medical Sciences & Peking Union Medical CollegeChina | 37.5 | 21.0% | 4.0× | 18 | -7.0% |
Universities only. Score blends excellence (30%), specialisation (25%), size (20%), growth (15%) and international reach (10%), 2015–2022; growth compares 2010–14 with 2015–19.
Is Cancer-related Molecular Pathways research growing?
Output in 2018–2022 was 14% lower than in 2013–2017, peaking in 2011. The fastest-growing topics are Cancer-related Molecular Pathways.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Which topics inside it are moving
Growth and decline on one axis around a shared zero. Two lists side by side hide the thing that matters: whether the growth dwarfs the decline, or the other way round.